- Home
- NUVB vs NCDL Comparison
NUVB vs NCDL Comparison
Compare NUVB & NCDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- NCDL
- Stock Information
- Founded
- NUVB 2018
- NCDL 2019
- Country
- NUVB United States
- NCDL United States
- Employees
- NUVB N/A
- NCDL N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- NCDL
- Sector
- NUVB Health Care
- NCDL
- Exchange
- NUVB Nasdaq
- NCDL NYSE
- Market Cap
- NUVB 679.9M
- NCDL 814.1M
- IPO Year
- NUVB N/A
- NCDL N/A
- Fundamental
- Price
- NUVB $2.50
- NCDL $16.86
- Analyst Decision
- NUVB Strong Buy
- NCDL Hold
- Analyst Count
- NUVB 6
- NCDL 4
- Target Price
- NUVB $7.83
- NCDL $16.63
- AVG Volume (30 Days)
- NUVB 5.9M
- NCDL 162.7K
- Earning Date
- NUVB 08-04-2025
- NCDL 08-06-2025
- Dividend Yield
- NUVB N/A
- NCDL 12.44%
- EPS Growth
- NUVB N/A
- NCDL N/A
- EPS
- NUVB N/A
- NCDL N/A
- Revenue
- NUVB $10,957,000.00
- NCDL N/A
- Revenue This Year
- NUVB $98.78
- NCDL N/A
- Revenue Next Year
- NUVB $489.71
- NCDL N/A
- P/E Ratio
- NUVB N/A
- NCDL N/A
- Revenue Growth
- NUVB N/A
- NCDL N/A
- 52 Week Low
- NUVB $1.54
- NCDL $14.21
- 52 Week High
- NUVB $3.97
- NCDL $18.01
- Technical
- Relative Strength Index (RSI)
- NUVB 63.18
- NCDL 54.70
- Support Level
- NUVB $2.06
- NCDL $16.51
- Resistance Level
- NUVB $2.62
- NCDL $17.08
- Average True Range (ATR)
- NUVB 0.15
- NCDL 0.26
- MACD
- NUVB 0.04
- NCDL -0.03
- Stochastic Oscillator
- NUVB 78.71
- NCDL 50.00
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP
Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.